Showing results (1-10 of 359) with videos related to
Sort By:
Pageof 36
PET Clinics|July 18, 2014
Yttrium-based therapy for neuroendocrine tumorsLisa Bodei, Marta Cremonesi, Giovanni PaganelliSeminars in Nuclear Medicine|April 20, 2002
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology GroupMarco Chinol, Lisa Bodei, Marta Cremonesi, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2006
Dosimetry in Peptide radionuclide receptor therapy: a reviewMarta Cremonesi, Mahila Ferrari, Lisa Bodei, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2004
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursLisa Bodei, Marta Cremonesi, Chiara Grana, et al.Thoracic Surgery Clinics|July 29, 2014
Peptide receptor radionuclide therapy for advanced neuroendocrine tumorsLisa Bodei, Marta Cremonesi, Mark Kidd, et al.European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2012
Yttrium-labelled peptides for therapy of NETLisa Bodei, Marta Cremonesi, Chiara M Grana, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 5, 2006
Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOCMahila Ferrari, Marta Cremonesi, Mirco Bartolomei, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2008
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsLisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I studyLisa Bodei, Marta Cremonesi, Stefania Zoboli, et al.European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2009
Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningiomaMirco Bartolomei, Lisa Bodei, Concetta De Cicco, et al.Pageof 36